SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis

S Berardis, A Verroken, A Vetillart, C Struyf, M Gilbert, D Gruson, S Gohy, S Berardis, A Verroken, A Vetillart, C Struyf, M Gilbert, D Gruson, S Gohy

Abstract

Background: In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown.

Methods: After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data.

Results: Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases.

Conclusions: Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis.

Keywords: COVID-19; Cystic fibrosis; SARS-CoV-2; Seroprevalence.

Conflict of interest statement

Declaration of Competing Interest The authors have declared that no conflict of interest exists.

Copyright © 2020. Published by Elsevier B.V.

References

    1. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 doi: 10.1001/jamainternmed.2020.0994.
    1. Cutting G. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2014;16(1):45–56. doi: 10.1038/nrg3849.
    1. Renk H., Regamey N., Hartl D. Influenza A(H1N1)pdm09 and cystic fibrosis lung disease: a systematic meta-analysis. PLoS ONE. 2014;9(1):e78583. doi: 10.1371/journal.pone.0078583.
    1. Cosgriff R., Ahern S., Bell S., Brownlee K., Burgel P.-.R., Byrnes C., et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros. 2020 doi: 10.1016/j.jcf.2020.04.012.
    1. Farrell P.M., White T.B., Ren C.L., Hempstead S.E., Accurso F., Derichs N., et al. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. J Pediatr. 2017 doi: 10.1016/j.jpeds.2016.09.064.
    1. Padoan A., Cosma C., Sciacovelli L., Faggian D., Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020;(Apr 16) doi: 10.1515/cclm-2020-0443. .
    1. Lippi G., Salvagno G.L., Pegoraro M., Militello V., Caloi C., Peretti A., et al. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin Chem Lab Med. 2020;58(7):1156–1159. doi: 10.1515/cclm-2020-0473.
    1. Montesinos I., Gruson D., Kabamba B., Dahma H., Van Den Wijngaert S., Reza S., et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin virol. 2020;128(Jul) doi: 10.1016/j.jcv.2020.104413.
    1. (accessed May 27, 2020).
    1. Gautret P., Lagier J.-.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;(Mar 20) doi: 10.1016/j.ijantimicag.2020.105949.
    1. Xiang F., Wang X., He X., Peng Z., Yang B., Zhang J., et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis. 2020;(Apr 19) doi: 10.1093/cid/ciaa461.
    1. Theel E., Slev P., Wheeler S., Couturier M.G., Wong S.J., Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol. 2020 doi: 10.1128/JCM.00797-20.
    1. Robbiani D.F., Gaebler C., Muecksch F., Lorenzi J.C.C., Wang Z., Cho A., et al. Convergent antibody response to SARS-CoV-2 in convalescent individuals. Nature. 2020 doi: 10.1101/2020.05.13.092619.
    1. Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y., et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;(Mar 28):ciaa344. doi: 10.1093/cid/ciaa344.
    1. Zeng Z., Chen L., Pan Y., Deng Q., Ye G., Li Y., et al. Re: profile of specific antibodies to SARS-CoV-2 : the first report. J Infect. 2020;(Apr 10) doi: 10.1016/j.jinf.2020.03.052. S0163-4453(20)30180-8.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner